Enhancement of radiotherapeutic effectiveness by temperature-sensitive liposomal 1-methylxanthine

International Journal of Pharmaceutics

Volumn 372, Issue 1-2, 2009, Pages 132-139

  Jeong, Seong Yun ^a   Yi, So Lyoung ^b   Lim, Sun Kyung ^c   Park, Sung Jin ^a   Jung, Joohee ^a   Woo, Ha Na ^a   Song, Si Yeol ^b   Kim, Jin Seok ^c   Lee, Jung Shin ^a,b   Lee, Jin Seong ^a,b   Park, Heon Joo ^a,d   Choi, Eun Kyung ^a,b  

^a Asan Medical Center   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Sookmyung Women's University   (South Korea)

^d Inha University School of Medicine   (South Korea)

Author keywords

1 Methylxanthine; Liposome; Radiosensitivity; Temperature sensitive; Xenograft

Indexed keywords

1 METHYLXANTHINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTHERMIC THERAPY; IN VIVO STUDY; IONIZING RADIATION; LIPOSOMAL DELIVERY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RADIATION RESPONSE; RADIOSENSITIVITY; TEMPERATURE SENSITIVITY; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, NUDE; RADIATION-SENSITIZING AGENTS; TEMPERATURE; XANTHINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 64149129431     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.12.040     Document Type: Article

References (38)

1. Ahn J.Y., Schwarz J.K., Piwnica-Worms H., and Canman C.E. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res. 60 (2000) 5934-5936
2. Akinaga S., Nomura K., Gomi K., and Okabe M. Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemother. Pharmacol. 32 (1993) 183-189
3. Anderson H.J., Andersen R.J., and Roberge M. Inhibitors of the G2 DNA damage checkpoint and their potential for cancer therapy. Prog. Cell Cycle Res. 5 (2003) 423-430
4. Asaad N.A., Zeng Z.C., Guan J., Thacker J., and Iliakis G. Homologous recombination as a potential target for caffeine radiosensitization in mammalian cells: reduced caffeine radiosensitization in XRCC2 and XRCC3 mutants. Oncogene 19 (2000) 5788-5800
5. Blasina A., Paegle E.S., and McGowan C.H. The role of inhibitory phosphorylation of CDC2 following DNA replication block and radiation-induced damage in human cells. Mol. Biol. Cell. 8 (1997) 1013-1023
6. Bunch R.T., and Eastman A. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin. Cancer Res. 2 (1996) 791-797
7. Busby E.C., Leistritz D.F., Abraham R.T., Karnitz L.M., and Sarkaria J.N. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res. 60 (2000) 2108-2112
8. Choi E.K., Roberts K.P., Griffin R.J., Han T., Park H.J., and Song C.W. Effect of pH on radiation-induced p53 expression. Int. J. Radiat. Oncol. Biol. Phys. 60 (2004) 1264-1271
9. Choi E.K., Ji I.M., Lee S.R., Kook Y.H., Griffin R.J., Lim B.U., Kim J.S., Lee D.S., Song C.W., and Park H.J. Radiosensitization of tumor cells by modulation of ATM kinase. Int. J. Radiat. Biol. 82 (2006) 277-283
10. Cortez D., Wang Y., Qin J., and Elledge S.J. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 286 (1999) 1162-1166
11. Duncan R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2 (2003) 347-360
12. Fernandez-Capetillo O., Chen H.T., Celeste A., Ward I., Romanienko P.J., Morales J.C., Naka K., Xia Z., Camerini-Otero R.D., Motoyama N., Carpenter P.B., Bonner W.M., Chen J., and Nussenzweig A. DNA damage-induced G2-M checkpoint activation by histone H2AX and 53BP1. Nat. Cell. Biol. 4 (2002) 993-997
13. Ferraretto A., Sonnino S., Soria M.R., and Masserini M. Characterization of biotinylated liposomes sensitive to temperature and pH: new tools for anti-cancer drug delivery. Chem. Phys. Lipids 82 (1996) 133-139
14. Fuse E., Tanii H., Kurata N., Kobayashi H., Shimada Y., Tamura T., Sasaki Y., Tanigawara Y., Lush R.D., Headlee D., Figg W.D., Arbuck S.G., Senderowicz A.M., Sausville E.A., Akinaga S., Kuwabara T., and Kobayashi S. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res. 58 (1998) 3248-3253
15. Graves P.R., Yu L., Schwarz J.K., Gales J., Sausville E.A., O'Connor P.M., and Piwnica-Worms H. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J. Biol. Chem. 275 (2000) 5600-5605
16. Iliakis G., Wang Y., Guan J., and Wang H. DNA damage checkpoint control in cells exposed to ionizing radiation. Oncogene 22 (2003) 5834-5847
17. Ismail I.H., Nystrom S., Nygren J., and Hammarsten O. Activation of ataxia telangiectasia mutated by DNA strand break-inducing agents correlates closely with the number of DNA double strand breaks. J. Biol. Chem. 280 (2005) 4649-4655
18. Jackson J.R., Gilmartin A., Imburgia C., Winkler J.D., Marshall L.A., and Roshak A. An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage. Cancer Res. 60 (2000) 566-572
19. Jha M.N., Bamburg J.R., Bernstein B.W., and Bedford J.S. Caffeine eliminates gamma-ray-induced G2-phase delay in human tumor cells but not in normal cells. Radiat. Res. 157 (2002) 26-31
20. Kohn E.A., Ruth N.D., Brown M.K., Livingstone M., and Eastman A. Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation. J. Biol. Chem. 277 (2002) 26553-26564
21. Kono K., Nakai R., Morimoto K., and Takagishi T. Thermosensitive polymer-modified liposomes that release contents around physiological temperature. Biochim. Biophys. Acta 1416 (1999) 239-250
22. Kopecek J. Smart and genetically engineered biomaterials and drug delivery systems. Eur. J. Pharm. Sci. 20 (2003) 1-16
23. Lau C.C., and Pardee A.B. Mechanism by which caffeine potentiates lethality of nitrogen mustard. Proc. Natl. Acad. Sci. U.S.A. 79 (1982) 2942-2946
24. Lavin M.F., Birrell G., Chen P., Kozlov S., Scott S., and Gueven N. ATM signaling and genomic stability in response to DNA damage. Mutat. Res. 569 (2005) 123-132
25. Lim S.K., Park H.J., Choi E.K., and Kim J.S. Long-circulating, temperature sensitive and EGFR-targeted liposomes for drugs delivery. Key Eng. Mater. 342-343 (2007) 537-540
26. Matsuoka S., Huang M., and Elledge S.J. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282 (1998) 1893-1897
27. Needham D., and Dewhirst M.W. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv. Drug Deliv. Rev. 53 (2001) 285-305
28. Park H.J., Lee S.H., Chung H., Rhee Y.H., Lim B.U., Ha S.W., Griffin R.J., Lee H.S., Song C.W., and Choi E.K. Influence of environmental pH on G2-phase arrest caused by ionizing radiation. Radiat. Res. 159 (2003) 86-93
29. Russell K.J., Wiens L.W., Demers G.W., Galloway D.A., Le T., Rice G.C., Bianco J.A., Singer J.W., and Groudine M. Preferential radiosensitization of G1 checkpoint-deficient cells by methylxanthines. Int. J. Radiat. Oncol. Biol. Phys. 36 (1996) 1099-1106
30. Sancar A., Lindsey-Boltz L.A., Unsal-Kacmaz K., and Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem. 73 (2004) 39-85
31. Sarkaria J.N., Busby E.C., Tibbetts R.S., Roos P., Taya Y., Karnitz L.M., and Abraham R.T. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res. 59 (1999) 4375-4382
32. Sausville E.A., Arbuck S.G., Messmann R., Headlee D., Bauer K.S., Lush R.M., Murgo A., Figg W.D., Lahusen T., Jaken S., Jing X., Roberge M., Fuse E., Kuwabara T., and Senderowicz A.M. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J. Clin. Oncol. 19 (2001) 2319-2333
33. Szoka Jr. F., and Papahadjopoulos D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc. Natl. Acad. Sci. U.S.A. 75 (1978) 4194-4198
34. Tam S.W., and Schlegel R. Staurosporine overrides checkpoints for mitotic onset in BHK cells. Cell. Growth Differ. 3 (1992) 811-817
35. Teicher B.A., Holden S.A., Herman T.S., Epelbaum R., Pardee A.B., and Dezube B. Efficacy of pentoxifylline as a modulator of alkylating agent activity in vitro and in vivo. Anticancer Res. 11 (1991) 1555-1560
36. Walters R.A., Gurley L.R., and Tobey R.A. Effects of caffeine on radiation-induced phenomena associated with cell-cycle traverse of mammalian cells. Biophys. J. 14 (1974) 99-118
37. Wang Q., Fan S., Eastman A., Worland P.J., Sausville E.A., and O'Connor P.M. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J. Natl. Cancer Inst. 88 (1996) 956-965
38. Wang H., Boecker W., Wang X., Guan J., Thompson L.H., Nickoloff J.A., and Iliakis G. Caffeine inhibits homology-directed repair of I-SceI-induced DNA double-strand breaks. Oncogene 23 (2004) 824-834